Recent success of PSMA (Prostate-Specific Membrane Antigen) ligands labeled with PET (Positron Emission Tomography) radionuclides, particularly with 68Ga, has increased the application of nuclear imaging in the diagnosis of prostate cancer in different clinical settings, such as for primary staging, assessment of therapeutic responses, and treatment planning [4–9]. The gene discussed is FOLH1; the disease is prostate carcinoma.